Peer-reviewed veterinary case report
PD-L1 protein in canine B cell lymphoma drops with MEK inhibitor
By Kumar, S R et al.·Published in Veterinary and comparative oncology·2017·School of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
- Species:
- dog
Plain-English summary
A dog with B cell lymphoma, a type of cancer affecting the immune system, showed high levels of a protein called PD-L1 that can suppress the immune response. Researchers found that using certain drugs, known as MEK inhibitors, reduced the levels of PD-L1 in the cancer cells. This suggests that these inhibitors could be a potential treatment option, helping to boost the dog's immune system to fight the cancer more effectively. While this study is still in the research phase, it opens up new possibilities for treating dogs with this type of lymphoma.
People also search for: dog B cell lymphoma treatment · MEK inhibitors for dog cancer · immune system cancer treatment dogs
Abstract
Programmed death ligand 1 (PD-L1) expression in antigen-presenting cells and tumors can inhibit T cell-mediated immunity. In this study, PD-L1 mRNA and protein expression was evaluated in canine B cell lymphoma (CLL17-71), large T-cell leukemia (CLGL-90), B cell leukemia (GL-1) and primitive leukocyte round cell neoplasia (CLL-1390). Variable PD-L1 mRNA and protein were observed in these cells with high endogenous expression present in CLL17-71 cells. PD-L1 protein was also observed in canine patient B cell lymphoma tissues using immunostaining. PD-L1 and signal transducer and activator of transcription 1 ( STAT1 ) mRNA expression were reduced in the presence of mitogen-activated protein kinase kinase 1.2 (MEK1/2) inhibitors RDEA119 and AZD6244 in CLL 17-71 cells. RDEA119 had similar effect on PD-L1 and STAT-1 in IFN-γ activated CLL-1390 cells. Overall, these results indicate that PD-L1 is expressed in canine B cell lymphoma. Its inhibition by MEK1/2 inhibitors suggests a possible treatment strategy using targeted drugs which likely could enhance antitumor immune response.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28111882/